Physician profile
Susan E Engle
NPI 1467831719
$2,688.71
in general payments reported to CMS, 2019-2025
28 companies · $289 in 2025
The $289 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $343 · 2022: $1,059 · 2023: $525 · 2024: $474 · 2025: $289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,287.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,287.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $718.61 | 2021-2025 | |
| Glaxosmithkline, LLC. | $351.50 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $145.89 | 2022 | |
| Lilly USA, LLC | $142.74 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Abbott Laboratories | $141.29 | 2022-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Novo Nordisk INC | $126.52 | 2021-2025 | Wegovy |
| Tactile Systems Technology INC | $104.38 | 2022 | |
| Boston Scientific Corporation | $100.67 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $79.72 | 2021-2023 | Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $73.22 | 2021-2025 | Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $71.88 | 2022 | |
| Amgen INC. | $67.20 | 2023-2025 | Repatha, Otezla, Repatha |
| Biohaven Pharmaceuticals, INC. | $60.01 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $54.86 | 2023 | Austedo |
| Pfizer INC. | $54.11 | 2023-2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $53.88 | 2021-2024 | |
| Alexion Pharmaceuticals, INC. | $49.21 | 2024 | Ultomiris |
| Inari Medical, INC. | $47.33 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Janssen Pharmaceuticals, INC | $41.47 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $35.27 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.08 | 2022 | |
| Merck Sharp & Dohme LLC | $28.59 | 2023 | Verquvo, Belsomra |
| Axsome Therapeutics, INC. | $26.18 | 2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $25.82 | 2025 | Caplyta |
| Biogen, INC. | $17.61 | 2024 | Skyclarys |
| Myovant Sciences INC. | $15.22 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $13.23 | 2022 | |
| Cequr Corporation | $12.22 | 2024 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Engle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.